Antiretroviral therapy in children: Recent advances

Indian Journal of Pediatrics

Volumn 79, Issue 12, 2012, Pages 1625-1633

  Lodha, Rakesh ^a   Manglani, Mamta ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b LOKMANYA TILAK MUNICIPAL MEDICAL COLLEGE AND GENERAL HOSPITAL   (India)

Author keywords

Antiretroviral therapy; Children; HIV AIDS; Recent advances

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLERGIC REACTION; ARTICLE; CHILD; DRUG POTENCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; MORBIDITY; MORTALITY; TREATMENT OUTCOME; VIRUS REPLICATION; WORLD HEALTH ORGANIZATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INFANT; INFANT, NEWBORN; PEDIATRICS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84878443540     PISSN: 00195456     EISSN: 09737693     Source Type: Journal    
DOI: 10.1007/s12098-012-0903-9     Document Type: Article

References (31)

1. Fisher AG, Collalti E, Ratner L, Gallo RC, Wong-Staal F. A molecular clone of HTLV-III with biological activity. Nature. 1985;316:262-5.
2. Gadelha AJ, Accacio N, Costa RL, et al. Morbidity and survival in advanced AIDS in Rio de Janeiro, Brazil. Rev Inst Med Trop Sao Paulo. 2002;44:179-86.
3. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet. 2006;368:505-10.
4. Bartlett JG, Gallant JE. Medical management of HIV infection. Baltimore: Johns Hopkins Medicine Health Publishing Business Group;2004; pp 49.
5. Molina JM, Podsadecki TJ, Johnson MA, et al. A Lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 wk. AIDS Res Hum Retrovir. 2007;23:1505-14.
6. Violari A, Cotton MF, Gibb DM, CHER Study team, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359:2233-44.
7. World Health Organization. Antiretroviral therapy of HIV infection in infants and children: towards universal access: recommendations for a public health approach - 2010 revision. Geneva 2010.
8. PENTA Steering Committee. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med. 2009;10:591-613.
9. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. August 11, 2011; pp 1-268.Available at http://aidsinfo.nih.gov/ ContentFiles/PediatricGuidelines.pdf Accessed (September 5, 2011).
10. Guidelines for HIV care and treatment in Infants and Children. November 2006. published by IAP and NACO, available on www.nacoonline.org.
11. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med. 2010;363:1510-20.
12. Palumbo P, Violari A, Lindsey L, et al. NVP- vs LPV/r-based ART among HIV + infants in resource-limited settings: the IMPAACT P1060 trial [abstract no.129LB]. 18th Conference on Retroviruses and Opportunistic Infections;2011 Feb 27-Mar 2; Boston (MA).
13. The PENPACT-1 (PENTA 9/PACTG 390) Study Team. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis. 2011;11:273-83.
14. Mulenga V, Cook A, Walker AS, et al. Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial. Clin Infect Dis. 2010;51:1081-9.
15. World Health Organization. Rapid advice. Antiretroviral therapy for HIV infection in adults and adolescents. Geneva: WHO; 2009.
16. Kumarasamy N, Venkatesh KK, Cecelia AJ, et al. Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. AIDS Patient Care STDs. 2008;22:337-44.
17. Shah I. Adverse effects of antiretroviral therapy in HIV-1 infected children. J Trop Pediatr. 2006;52:244-8.
18. Agarwal D, Chakravarty J, Chaube L, Rai M, Agrawal NR, Sundar S. High incidence of zidovudine induced anaemia in HIV infected patients in eastern India. Indian J Med Res. 2010;132:386-9.
19. Romanelli F, Empey K, Pomeroy C. Macrocytosis as an indicator of medication (zidovudine) adherence in patients with HIV infection. AIDS Patient Care STDS. 2002;16:405-11.
20. Paediatric European Network for Treatment of AIDS (PENTA). Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 y in children. AIDS. 2007;21:947-55.
21. McKinney Jr RE, Rodman J, Hu C, et al. Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: pediatric AIDS clinical trials group protocol P1021. Pediatrics. 2007;120:e416-23.
22. Scherpbier HJ, Bekker V, Pajkrt D, Jurliaans S, Lange JM, Kujjpers TW. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an Efavirenz-containing regimen. Pediatrics. 2007;119:e705-15.
23. Fagard C, Oxenius A, Günthard H, et al; Swiss HIV Cohort Study. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med. 2003;163:1220-6.
24. Yerly S, Gunthard HF, Fagard C, et al. Swiss HIV Cohort Study. Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. AIDS. 2004;18:1951-3.
25. Lori F, Lisziewicz J. Structured treatment interruptions for the management of HIV infection. JAMA. 2001;286:2981-7.
26. Lori F, Maserati R, Foli A, Seminari E, Timpone J, Lisziewicz J. Structured treatment interruptions to control HIV. Lancet. 2000;355:287-8.
27. Miller V, Sabin C, Hertogs K, et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS. 2000;14:2857-67.
28. Lori F, Lewis MG, Xu J, et al. Control of HIV rebound through structured treatment interruptions during early infection. Science. 2000;290:1591-3.
29. Giard M, Boibieux A, Ponceau B, et al. Treatment interruption in HIV infected patients: clinical and biological evolution. Med Malad Infect. 2005;35:525-9.
30. Borkowsky W, Yogev R, Muresan P, et al. Planned multiple exposures to autologous virus in HIV type 1-infected pediatric populations increases HIVspecific immunity and reduces HIV viremia. AIDS Res Hum Retrovir. 2008;24:401-11.
31. Palacios GC, Sanchez LM, Briones E, et al. Structured interruptions of highly active antiretroviral therapy in cycles of 4 wk off/12 wk on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds. Int J Infect Dis. 2010;14:e34-40.